Contact
searchSearch
HMP Global
Login

HER2 Videos

Paolo Tarantino, MD, PhD
Videos
Long-Term Results Support De-escalated Neoadjuvant Therapy in HER2-Positive Breast Cancer
07/22/2026
Paolo Tarantino, MD, PhD
Paolo Tarantino, MD, PhD, discusses 5-year results from the phase 2 DAPHNe trial showing that neoadjuvant paclitaxel, trastuzumab, and pertuzumab achieved excellent long-term outcomes with no distant recurrences among patients with...
Paolo Tarantino, MD, PhD, discusses 5-year results from the phase 2 DAPHNe trial showing that neoadjuvant paclitaxel, trastuzumab, and pertuzumab achieved excellent long-term outcomes with no distant recurrences among patients with...
Paolo Tarantino, MD, PhD,...
07/22/2026
Oncology
Erika Hamilton, MD
Videos
Tucatinib Demonstrates Consistent Benefit Across First-Line HER2-Positive Metastatic Breast Cancer Populations
06/26/2026
Erika Hamilton, MD
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses...
06/26/2026
Oncology
Robert Stein, PhD
Videos
Prosigna-Guided Treatment Safely Reduces Chemotherapy Use in HR-Positive, HER2-Negative Early Breast Cancer
06/19/2026
Robert Stein, PhD
Robert Stein, PhD, discusses results from the phase 3 OPTIMA trial showing that Prosigna-guided treatment identified approximately 68% of patients with HR-positive, HER2-negative early breast cancer who could safely avoid chemotherapy without...
Robert Stein, PhD, discusses results from the phase 3 OPTIMA trial showing that Prosigna-guided treatment identified approximately 68% of patients with HR-positive, HER2-negative early breast cancer who could safely avoid chemotherapy without...
Robert Stein, PhD, discusses...
06/19/2026
Oncology
Mabel Mardones, MD
Videos
Giredestrant Demonstrates Favorable Safety Profile but Fails to Significantly Improve PFS in HR-Positive, HER2-Negative Metastatic Breast Cancer
06/18/2026
Mabel Mardones, MD
Mabel Mardones, MD, discusses results from the phase 3 persevERA trial in which giredestrant plus palbociclib achieved a numerical progression-free survival improvement over letrozole plus palbociclib in patients with HR-positive,...
Mabel Mardones, MD, discusses results from the phase 3 persevERA trial in which giredestrant plus palbociclib achieved a numerical progression-free survival improvement over letrozole plus palbociclib in patients with HR-positive,...
Mabel Mardones, MD, discusses...
06/18/2026
Oncology
Kathleen Moore, MD
Videos
Trastuzumab Pamirtecan Produces Durable Responses Across HER2 Expression Levels in Advanced Endometrial Cancer
06/17/2026
Kathleen Moore, MD
Kathleen Moore, MD, discusses updated phase 1/2 data showing that trastuzumab pamirtecan achieved durable responses and encouraging survival outcomes across HER2-expressing subgroups of advanced endometrial cancer, with the greatest activity...
Kathleen Moore, MD, discusses updated phase 1/2 data showing that trastuzumab pamirtecan achieved durable responses and encouraging survival outcomes across HER2-expressing subgroups of advanced endometrial cancer, with the greatest activity...
Kathleen Moore, MD, discusses...
06/17/2026
Oncology
Oleg Gluz, MD
Videos
Longer Docetaxel-Based Chemotherapy Associated With Improved Outcomes in High-Risk HR-Positive, HER2-Negative Breast Cancer
06/11/2026
Oleg Gluz, MD
Oleg Gluz, MD, discusses pooled analyses from the PlanB and ADAPT trials suggesting that longer docetaxel-based chemotherapy may improve outcomes in patients with high-risk HR-positive, HER2-negative early breast cancer.
Oleg Gluz, MD, discusses pooled analyses from the PlanB and ADAPT trials suggesting that longer docetaxel-based chemotherapy may improve outcomes in patients with high-risk HR-positive, HER2-negative early breast cancer.
Oleg Gluz, MD, discusses pooled...
06/11/2026
Oncology
Davide Ciardiello, MD
Videos
HER2 Alterations May Influence Response to Cetuximab in Metastatic Colorectal Cancer
03/11/2026
Davide Ciardiello, MD
Davide Ciardiello, MD, discusses an exploratory analysis of the CAPRI2-GOIM study showing that HER2 mutations and HER2 amplification may have distinct prognostic and predictive implications for patients with RAS/BRAF wild-type metastatic...
Davide Ciardiello, MD, discusses an exploratory analysis of the CAPRI2-GOIM study showing that HER2 mutations and HER2 amplification may have distinct prognostic and predictive implications for patients with RAS/BRAF wild-type metastatic...
Davide Ciardiello, MD, discusses...
03/11/2026
Oncology
Sanjay Popat, MD, PhD
Videos
First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
11/13/2025
Sanjay Popat, MD
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology
Paolo Tarantino, MD, and Guillermo Villacampa, MS
Videos
HER2DX Demonstrates Clinical Promise Among Patients With HER2-Positive Early Breast Cancer
08/25/2025
Paolo Tarantino, MD, PhD
Paolo Tarantino, MD, and Guillermo Villacampa, MS, discuss results from an individual patient-level meta-analysis which analyzed HER2DX, a genomic test to stratify risk, among patients with HER2-positive early breast cancer.
Paolo Tarantino, MD, and Guillermo Villacampa, MS, discuss results from an individual patient-level meta-analysis which analyzed HER2DX, a genomic test to stratify risk, among patients with HER2-positive early breast cancer.
Paolo Tarantino, MD, and...
08/25/2025
Oncology
Seth Wander, MD, PhD; Rachel Abelman, MD, Massachusetts General Brigham Cancer Center
Videos
Omitting Carboplatin from Neoadjuvant Regimen for Patients With HER2-Positive Early Breast Cancer
07/31/2025
Seth Wander, MD
Rachel Abelman, MD, and Seth Wander, MD, PhD, Massachusetts General Brigham Cancer Center, discuss the phase 3 neoCARHP study.
Rachel Abelman, MD, and Seth Wander, MD, PhD, Massachusetts General Brigham Cancer Center, discuss the phase 3 neoCARHP study.
Rachel Abelman, MD, and Seth...
07/31/2025
Oncology

Recent News

News
NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera
09/22/2026
Stephanie Holland
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines...
09/22/2026
Oncology
News
FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes
09/22/2026
Emily Estrada
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track...
09/22/2026
Oncology
News
Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer
09/22/2026
Stephanie Holland
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3...
09/22/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
09/21/2026
Emily Estrada
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3...
09/21/2026
Oncology
FDA Approval
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
09/18/2026
Stephanie Holland
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase...
09/18/2026
Oncology
FDA Alerts
FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer
09/17/2026
Emily Estrada
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental...
09/17/2026
Oncology
News
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
09/17/2026
Emily Estrada
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE...
09/17/2026
Oncology
News
Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation
09/17/2026
Emily Estrada
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial...
09/17/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer
09/16/2026
Stephanie Holland
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...
Results from the phase 3...
09/16/2026
Oncology
FDA Alerts
FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access
09/16/2026
Stephanie Holland
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...
The FDA updated the prescribing...
09/16/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use